Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2025; 17(10): 109398
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.109398
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.109398
Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics
Chen-Dong Wang, Jia Song, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Bi-Xiang Zhang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Co-corresponding authors: Bi-Xiang Zhang and Jia Song.
Author contributions: Song J contributed to conceptualization; Wang CD contributed to writing original draft preparation; Song J, Wang CD and Zhang BX writing review and editing; All authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia Song, MD, Associate Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. tjhsongjia@hust.edu.cn
Received: May 12, 2025
Revised: July 18, 2025
Accepted: September 9, 2025
Published online: October 15, 2025
Processing time: 158 Days and 5.7 Hours
Revised: July 18, 2025
Accepted: September 9, 2025
Published online: October 15, 2025
Processing time: 158 Days and 5.7 Hours
Core Tip
Core Tip: Lipid metabolic reprogramming is a hallmark of colorectal cancer, influencing tumor initiation, immune evasion, and therapeutic resistance. Targeting key nodes in lipid synthesis, oxidation, and transport, particularly in combination with immunotherapy, offers a transformative approach to colorectal cancer treatment. While preclinical models highlight the efficacy of metabolic-immune combinatory regimens, future studies should prioritize clinical translation of these strategies while addressing metabolic heterogeneity and microenvironmental crosstalk.